Edan Instruments (300206) Fundamentals 2026 — P/E 19.0x, Revenue Analysis | SniperIQ
Edan Instruments (300206) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥6.6B, trading at ¥11.31 on the SHZ. This SniperIQ fundamentals page covers Edan Instruments's valuation (P/E 19.0x, P/B 2.9x), profitability (net margin 16.5%), revenue (¥2.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Edan Instruments's market cap?
Edan Instruments (300206) has a market capitalization of approximately ¥6.6B, trading at ¥11.31 on the SHZ. Market cap moves with the live share price.
What is Edan Instruments's P/E ratio?
Edan Instruments's trailing twelve-month P/E ratio is 19.0x, with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Edan Instruments?
Edan Instruments runs a net profit margin of 16.5%, a gross margin of 58.4%, and an operating margin of 17.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Edan Instruments generate?
Edan Instruments reported revenue of ¥2.0B for fiscal year 2025, with net income of ¥306M and earnings per share (EPS) of 0.53. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Edan Instruments pay a dividend?
Edan Instruments offers a trailing dividend yield of about 2.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Edan Instruments financially healthy?
Edan Instruments carries a debt-to-equity ratio of 0.01x and a current ratio of 6.38x, with a market beta of 0.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Edan Instruments a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Edan Instruments (300206) the key facts are: market cap ¥6.6B, P/E 19.0x, revenue ¥2.0B, 52-week range 11.22-16.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Edan Instruments's full fundamentals live
Get Edan Instruments's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.